Showing 4801-4810 of 8788 results for "".
- Open-label Extension Study Shows Long-term Safety, Efficacy for UCB's Bimekizumab in PsOhttps://practicaldermatology.com/news/open-label-extension-study-shows-long-term-safety-efficacy-for-ucbs-bimekizumab-in-pso/2460883/New interim data from an open-label extension trial to assess the long-term safety, tolerability, and efficacy of bimekizumab show that the majority of patients who achieved complete or near complete skin clearance after 16 weeks of bimekizumab treatment maintained these responses through to
- Rinvoq Has Quicker Onset, Higher EASI Scores than Dupixent in Phase 3b Study of Adults with Atopic Dermatitishttps://practicaldermatology.com/news/rinvoq-bests-dupixent-in-phase-3b-study-of-adults-with-atopic-dermatitis/2460882/AbbVie’s JAK Inhibitor Rinvoq (upadacitinib) performed better than Dupixent (dupilumab) for primary and all ranked secondary endpoints in a phase 3b head-to-head study in adults with atopic dermatitis (AD), according to a
- Strand Therapeutics Scores Two Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancerhttps://practicaldermatology.com/news/strand-therapeutics-scores-two-grants-to-advance-programmable-long-lasting-mrna-therapeutics-for-melanoma-and-breast-cancer/2460881/Strand Therapeutics was awarded two Phase I Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop mRNA-based therapeutics for melanoma and triple negative breast cancer (TNBC). The total fund
- Bausch Health Plans IPO of Solta Medical Aesthetics Unithttps://practicaldermatology.com/news/bausch-health-plans-ipo-of-solta-medical-aesthetics-unit/2460880/Bausch Health Companies Inc. is planning to pursue an initial public offering (IPO) of its Solta Medical business. Solta’s portfolio includes the Thermage RF systems, Fraxel laser, Clear + Brilliant laser and VASER ultrasonic systems. The timing of the anticipated IPO, w
- ParaPRO’s Natroba for Scabies Now Availablehttps://practicaldermatology.com/news/parapros-natroba-for-scabies-now-available/2460877/ParaPRO’s Natroba (spinosad) Topical Suspension, 0.9% for scabies is now available. Natroba is the first new scabies drug to be approved by the U.S. Food and Drug Administration (FDA) in more than 30 years. Earlier this year, the company received FDA approval of its supp
- Dr. James Q. Del Rosso Named Senior Vice President of Clinical Research and Strategic Development at Advanced Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/dr-james-q-del-rosso-named-senior-vice-president-of-clinical-research-and-strategic-development-at-advanced-dermatology-and-cosmetic-surgery/2460873/James Q. Del Rosso, DO is now Senior Vice President of Clinical Research and Strategic Development at Advanced Dermatology and Cosmetic Surgery (ADCS). Dr. James Del Rosso and Ms. Allison Lynch, Chief Operating Officer of Pathology and Research Divisions, will oversee the company’
- FDA Delays Review of Pfizer’s Abrocitinib and Xeljanz Filingshttps://practicaldermatology.com/news/fda-delays-review-of-pfizers-abrocitinib-and-xeljanz-filings/2460870/The U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) goal dates for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis and the supplemental New Drug Application for Xeljanz/
- Allergan Aesthetics Continues Partnership with Girls Inc.https://practicaldermatology.com/news/allergan-aesthetics-continues-partnership-with-girls-inc/2460869/Allergan Aesthetics is starting its third consecutive year of partnership with Girls Inc. and debuting Empowering Confidence Workshops, a nationwide mentoring initiative. Based on a 2020 Girls Inc. report, many girls have a hard time picturing themselves in science, technology, eng
- LiVDerm Brings SBS Part II to Hollywood, FL this Fallhttps://practicaldermatology.com/news/livderm-brings-sbs-part-ii-to-hollywood-fl-this-fall/2460868/SBS Part II: The Aesthetic Dermatology Summit comes to Hollywood, FL, September 23-25, closing out the two-part 19th Annual South Beach Symposium. Produced by LiVDerm, the event is centered on the latest and most re
- PASI-HD: Modification to PsO Severity Scale Aims at Mild-to-Moderate Diseasehttps://practicaldermatology.com/news/pasi-hd-modification-to-pso-severity-scale-aims-at-mild-to-moderate-disease/2460867/A new modification to the Psoriasis Area and Severity Index (PASI) aims to address limitations of the scale when used to assess mild-to-moderate disease. PASI-high discrimination (PASI-HD), designed to be used in clinical trials among patients for whom the areas of affected body surface are less